Other gains came in at RMB 17 million, an increase of 28% over the previous corresponding period. The increase was mainly due to returns from short-term investments and government bonds.
SINGAPORE (April 28): Tianjin Zhongxin Pharmaceutical reported a 12% rise in 1Q earnings to RMB 133.7 million ($27 million) from a year ago.
Revenue fell 11% to RMB 1.5 billion but gross profit margin increased to 37.4% from 31.6%.
